The new antibiotics

Emergency Medicine Clinics of North America

Volumn 18, Issue 4, 2000, Pages 671-708

  Birnbaumer, Diane ^a,b   Fernández Frackelton, Madonna ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; AZITHROMYCIN; CAFFEINE; CARBACEPHEM DERIVATIVE; CEFDINIR; CEFEPIME; CEFPIROME; CEFTIBUTEN; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; LORACARBEF; MACROLIDE; MEROPENEM; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; ROXAR; SPARFLOXACIN; STEROID; THEOPHYLLINE; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ALLERGIC REACTION; ANTIBIOTIC THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERANCE; DRUG URINE LEVEL; DRUG USE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; PRIORITY JOURNAL; REVIEW; VAGINA CANDIDIASIS;

EID: 0033659462     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8627(05)70153-X     Document Type: Article

References (125)

1. Rapid emergence of resistance to cefepime during treatment: Correspondence
2. Treatment of vancomycin-resistant enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent of continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetation
3. Pharmacokinetics of cefepime in subjects with renal insufficiency
4. In vitro susceptibility testing procedures for fosfomycin tromethamine
5. In-vitro activity of dirithromycin in comparison with other new and established macrolides
6. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas
7. The overall safety of oral roxithromycin in paediatric clinical studies
8. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and humans
9. In vitro antibacterial activity of LY 333328, a new semisynthetic glycopeptide
10. Digoxin-macrolide drug interactions
11. Advances in the macrolides and quinolones
12. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin
13. Meropenem: A new, extremely broad-spectrum beta-lactam antibiotic for serious infections in pediatrics
14. The challenge of penicillin-resistant Streptococcus pneumonia meningitis. Current antibiotic therapy
15. Roxithromycin: Review of its antimicrobial activity
16. Cefdinir - A new oral cephalosporin
17. Cefepime (Maxipime): A new parenteral cephalosporin
18. Ceftibuten - A new oral cephalosporin
19. Clarithromycin and azithromycin
20. Penetration of meropenem into cerebrospinal fluid if patients with inflamed meninges
21. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis
22. Dirithromycin
23. Structure-activity and structure-side effect relationship for the quinolone antibacterials
24. Meropenem: A microbiological overview
25. Efthymiopoulos C: Pharmacokinetics of grepafloxacin
26. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections
27. In vitro activity of U-76,252 (CS-807), a new oral cephalosporin
28. Fosfomycin trometamol vs norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly
29. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumonia isolates from children with meningitis
30. Loracarbef: A new orally administered carbacephem antibiotic
31. Antimicrobial activity of fosfomycin in vitro
32. New antibiotics
33. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose
34. Antibacterial activity of cefprozil compared with those of 13 oral cephems and 3 macrolides
35. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates
36. The Sanford Guide to Antimicrobial Chemotherapy, ed 29
37. How do the newer oral antimicrobials stack up against traditional agents?
38. Sparfloxacin: A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy, and tolerability in lower respiratory infections
39. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wounds skin and soft tissue human infections
40. Grepafloxacin - A new fluoroquinolone
41. Comparative effectiveness and safety of cefdinir and amoxicillin/clavulanic acid in the treatment of acute community acquired bacterial sinusitis
42. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
43. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin
44. Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis
45. Macrolide susceptibility and β-lactamase production among Haemophilus influenzae isolates in the United States, 1996-1997
46. In vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections
47. Overview of electrocardiographic and cardiovascular safety for sparfloxacin
48. Ceftibuten: A review of antimicrobial activity, spectrum and other microbiological features
49. In vitro evaluation of sparfloxacin activity and spectrum against 24, 940 pathogens isolated in the United States and Canada
50. Ceftibuten (7432, SCH 39720): Comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines
51. Randomized trial of trovafoxacin and ofloxacin for single-dose therapy of gonorrhea
52. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus
53. Susceptibility of bacterial isolates to β-lactam antibiotics from US clinical trials over a 5-year period
54. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin resistant Streptococcus pneumonia
55. New direction for macrolide antibiotics: Pharmacokinetics and clinical efficacy
56. History of macrolide use in pediatrics
57. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis
58. Clarithromycin-induced ventricular tachycardia
59. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis
60. Rapid emergence of resistance to cefepime during treatment
61. Fluoroquinolone toxicity profiles: A review focusing on newer agents
62. Effects of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia. Comparison with a control cohort
63. A review of in-vitro antibacterial activity of quinopristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus
64. Efficacy of ceftibuten compared with amoxicillin for otitis media with effusion in infants and children
65. Levofloxacin and sparfloxacin: New quinolone antibiotics
66. Comparative safety and efficacy of clarithromycin and amoxicillin in the treatment of acute otitis media in children
67. Multicenter-controlled trial comparing ceftibuten with amoxicillin/clavulanic acid in the empiric treatment of acute otitis media
68. Meropenem - A new parenteral broad-spectrum antibiotic
69. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects
70. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprin-sulfamethoxazole, or rifampin, against Listeria monocytogenes
71. Rearming in the fight against bacteria
72. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethaprim in the treatment of uncomplicated lower urinary tract infections in women
73. Minimal inhibitory concentrations and minimal bacterial concentrations of quinupristin/dalfopristin against clinical isolates of Coryne-bacterium jeikeium and Listeria monocytogenes
74. In vitro antibacterial activity of trovafoxacin
75. In-vitro activity of quinupristin/dalforpristin compared with other widely used antibiotics against strains isolated from patients with endocarditis
76. Quinolone antibiotics in therapy of experimental pneumococcaI meningitis in rabbits
77. Safety of cefepime: A new extended-spectrum parenteral cephalosporin
78. Comparative in vitro activity and B-lactamase stability of FK 482, a new oral cephalosporin
79. New cephalosporins approved
80. Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecologic infections
81. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci
82. Pharmacokinetics and pharmacodynamics of newer macrolides
83. Safety profile of meropenem: International clinical experience based on the first 3125 patients treated with meropenem
84. In vitro activity of sparfloxacin against genital pathogens
85. Pharmacokinetics of roxthromycin in renal and hepatic failure and drug interactions
86. Ceftibuten vs. penicillin in group A beta-hemolytic streptococcal pharyngitis
87. Clarithromycin lowers plasm zidovudine levels in persons with human immunodeficiency virus infection
88. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centers
89. Worldwide safety experience with ceftibuten
90. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, and Legionella spp
91. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts
92. Safety profile of sparfloxacin in the treatment of respiratory tract infections
93. Prospective randomized comparison of cefepime and cefotaxime for the treatment of bacterial meningitis in infants and children
94. Comparison of cefprozil, cefpodoxime prozetil, loracarbef, cefixime and ceftibuten
95. Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: Results of an Italian multicenter survey
96. A randomized comparison of meropenem for the treatment of bacterial meningitis in adults
97. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections
98. Safety profile of dirithromycin
99. Sparfloxacin and Levofloxacin
100. Safety profile of grepafloxacin compared with other fluoroquinolones
101. Single-dose treatment of acute cystitis with fosfomycin tromethamine
102. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL- 60 cells
103. Five-day cefdinir treatment for streptococcal pharyngitis
104. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters
105. Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit mode of experimental meningitis
106. Future indications for macrolides
107. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infection
108. The safety profile of loracarbef: Clinical trials in respiratory, skin and urinary tract infections
109. Effects of renal dysfunction in the pharmacokinetics of loracarbef
110. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States measured by two methods
111. Wide-spectrum antibiotic activity of synthetic, amphipathic peptides
112. Trovafloxacin
113. Pharmacokinetic interaction between theophylline and other medications, Part I
114. Comparative activity of trovafoxacin, alone and in combination with other agents against gram-negative nonfermentative rods
115. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefprome, and meropenem against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology
116. Grepafloxacin
117. In vitro activity of trovafloxacin against 557 strains of anaerobic bacteria
118. Antibacterial activity of grepafloxacin
119. Dirithromycin: A new macrolide
120. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients
121. Cefepime versus ceftriaxone for empiric treatment of hospital patients with community-acquired pneumonia